Navigation Links
JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Date:7/5/2011

PARSIPPANY, N.J., July 5, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading marketer and manufacturer of sterile injectable products, is launching larger pack sizes for three products commonly used in acute care clinical settings: Adrenalin® (epinephrine injection, USP), Coly-Mycin® M Parenteral (colistimethate sodium, USP) and Pitocin® (oxytocin injection, USP synthetic).

Stuart Hinchen, CEO and President of JHP noted, "The larger pack size was developed to meet customer demand for cost savings and increased pharmacy efficiency by reducing packaging waste.  Our new multipacks allow pharmacy staff to open one carton containing multiple vials rather than open multiple cartons containing only one vial.  The efficiency is critical in busy pharmacies handling high volume products such as Adrenalin®, Coly-Mycin® M and Pitocin® and the cost savings are significant."  

Commenting on JHP's philosophy of marketing mature brand name products at competitive prices, Hinchen stated, "JHP is focused on meeting three key customer needs: quality, price and supply.  Reducing packaging waste in high volume products is an example of how we stay price competitive without sacrificing quality.  We are also vigilant in our efforts to provide the market with a reliable drug supply.  Since we manufacture our products, we have the dexterity to adapt to changing market demand which is crucial in today's injectable market."

All three products are still available in single vial packs to meet the needs of smaller clinical settings.  For more information about these products or other JHP products, please visit www.jhppharma.com/jhppricing and contact your local wholesaler or distributor.Products Available in a New Multipack Size* NDCProductStrengthVial SizePackSizeLatexFree42023-101-10Adrenalin® Injection1mg/mL30mL MDV10Yes42023-107-06Coly-Mycin® M Parenteral 150mg colistin base10mL SDV6Yes42023-116-02Pitocin® 10 units/mL10mL MDV25Yes*See full prescribing information for JHP products at http://www.jhppharma.com/products/About JHP Pharmaceuticals, LLC - JHP Pharmaceuticals, headquartered in New Jersey, is an integrated specialty healthcare company that acquires, develops, manufactures and sells sterile injectable products.  JHP markets 15 well-established branded pharmaceutical products primarily into the hospital segment.  JHP provides customers with a reliable supply of brand name products at competitive prices. 

JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas.  For more information, please visit www.jhppharma.com.

Contact:JHP Customer Service Tel: 1-877-547-4547MK246B
'/>"/>

SOURCE JHP Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... JERUSALEM , May 23, 2016 ... therapies for the treatment of cancer and orphan genetic ... of up to $4.4 million from the Israel Innovation ... the Israeli Ministry of Economy and Industry. The mission ... and entrepreneurship in various industries, including science and technology, ...
Breaking Medicine Technology:
(Date:5/24/2016)... IL (PRWEB) , ... May 24, 2016 , ... To ... created a new research award to examine gender differences in lung cancer. Today, the ... Research Innovation Project: Lung Cancer in Women Award, funded by the American Lung Association’s ...
(Date:5/24/2016)... California (PRWEB) , ... May 24, 2016 , ... ... technology, debuted a new corporate identity and website at its “Transforming Outcomes” User ... and other marketing enhancements reflect i2i’s ongoing success to set the market standard ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of ... will ever be totally eliminated, many human performance problems can be prevented. , How ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Regenerative Medicine ... breakthroughs in adult stem cell therapy technology, protocols and patient results as have been ... field to become a more accessible standard of care for patients worldwide. , As ...
Breaking Medicine News(10 mins):